非アルコール性脂肪性肝炎(NASH)バイオマーカーの世界市場2021-2028

◆英語タイトル:GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028
◆商品コード:INK21JU025
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2021年4月5日
◆ページ数:218
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートは非アルコール性脂肪性肝炎(NASH)バイオマーカーの世界市場について調査・分析し、調査範囲/手法、エグゼクティブサマリー、市場動向、主要分析、種類別(血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他)分析、エンドユーザー別(製薬・CRO産業、診断研究所、学術研究、病院)分析、地域別分析、競争状況などを掲載したものです。
・調査範囲/手法
・エグゼクティブサマリー
・市場動向
・主要分析
・非アルコール性脂肪性肝炎(NASH)バイオマーカーの世界市場規模:種類別(血清バイオマーカー、肝線維症バイオマーカー、アポトーシスバイオマーカー、酸化ストレスバイオマーカー、その他)
・非アルコール性脂肪性肝炎(NASH)バイオマーカーの世界市場規模:エンドユーザー別(製薬・CRO産業、診断研究所、学術研究、病院)
・地域別分析
・競争状況
【レポートの概要】

KEY FINDINGS
The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to grow with a CAGR of 20.65%, over the forecast period of 2021 to 2028. The market growth is mainly accredited to factors, such as, the rising NASH affected population, the surging awareness associated with non-alcoholic fatty liver disease, the increasing occurrence of chronic diseases, and the increasing prevalence of obesity and diabetes.
MARKET INSIGHTS
Non-alcoholic steatohepatitis (NASH), a highly destructive form of non-alcoholic fatty liver disease (NAFLD), often develops into more severe disorders, like hepatocellular carcinoma and cirrhosis. As a result, NASH is projected to surpass the hepatitis C virus infection and become the leading cause of liver transplantation, worldwide, over the upcoming decade. As these diseases progress, the liver experiences fibrosis and scarring, ultimately leading to cirrhosis. Liver fibrosis is likely to result in permanent organ damage, progress to hepatocellular carcinoma, and liver failure.
Obesity is a well-recognized epidemic, globally. The increasing incidence and prevalence of obesity have surged drastically, over the last ten years. For instance, according to the World Health Organization (WHO) 2020 report, more than 1.9 billion adults, aged 18 and older, were overweight in 2016. Out of which, 650 million individuals were obese. In addition, 38 million children below the age of 5 were overweight or obese in 2019. On the other hand, as per the 2020 Diabetes Research and Clinical Practice report, the worldwide prevalence of diabetes in 2019, was nearly 9.3%, and is expected to rise to 10.2% by 2030.
REGIONAL INSIGHTS
The global non-alcoholic steatohepatitis (NASH) biomarker market growth is evaluated by assessing the Asia Pacific, North America, Europe, and the rest of the world. The Asia Pacific is set to be the fastest-growing market over the forecast period. The region’s market growth is attributed to the enhanced healthcare infrastructure, improved economic conditions, and rising healthcare awareness in developing countries like China and India.
COMPETITIVE INSIGHTS
The industrial rivalry is anticipated to be moderate, owing to the unavailability of treatment. Besides, key market players focus on research, development, and partnerships, in order to introduce products into the market. Some of the leading companies operating in the market are, Merck & Co, AstraZeneca, Novartis AG, Pfizer Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. GROWING NASH AFFECTED POPULATION
3.1.2. SURGING PREVALENCE OF OBESITY AND DIABETES
3.1.3. INCREASING OCCURRENCE OF CHRONIC DISEASES
3.1.4. SURGING AWARENESS OF NON-ALCOHOLIC FATTY LIVER DISEASE
3.2. KEY RESTRAINTS
3.2.1. SIDE-EFFECTS AND RISKS ASSOCIATED WITH NASH THERAPEUTICS
3.2.2. LACK OF SPECIALIZED DIAGNOSTIC TEST FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
4. KEY ANALYTICS
4.1. PORTER’S FIVE FORCES ANALYSIS
4.1.1. THREAT OF NEW ENTRY
4.1.2. THREAT OF SUBSTITUTION
4.1.3. BUYER’S POWER
4.1.4. SUPPLIER’S POWER
4.1.5. COMPETITIVE RIVALRY
4.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
4.5. KEY INVESTMENT INSIGHTS
5. MARKET BY TYPE
5.1. SERUM BIOMARKER
5.2. HEPATIC FIBROSIS BIOMARKER
5.3. APOPTOSIS BIOMARKER
5.4. OXIDATIVE STRESS BIOMARKER
5.5. OTHER TYPES
6. MARKET BY END-USER
6.1. PHARMA & CRO INDUSTRY
6.2. DIAGNOSTIC LAB
6.3. ACADEMIC RESEARCH KEY
6.4. HOSPITAL
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. MARKET SIZE & ESTIMATES
7.1.2. KEY GROWTH ENABLERS
7.1.3. KEY CHALLENGES
7.1.4. KEY PLAYERS
7.1.5. COUNTRY ANALYSIS
7.1.5.1. THE UNITED STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1. MARKET SIZE & ESTIMATES
7.2.2. KEY GROWTH ENABLERS
7.2.3. KEY CHALLENGES
7.2.4. KEY PLAYERS
7.2.5. COUNTRY ANALYSIS
7.2.5.1. GERMANY
7.2.5.2. FRANCE
7.2.5.3. THE UNITED KINGDOM
7.2.5.4. ITALY
7.2.5.5. RUSSIA
7.2.5.6. BELGIUM
7.2.5.7. POLAND
7.2.5.8. REST OF EUROPE
7.3. ASIA PACIFIC
7.3.1. MARKET SIZE & ESTIMATES
7.3.2. KEY GROWTH ENABLERS
7.3.3. KEY CHALLENGES
7.3.4. KEY PLAYERS
7.3.5. COUNTRY ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. AUSTRALIA & NEW ZEALAND
7.3.5.4. INDIA
7.3.5.5. SOUTH KOREA
7.3.5.6. THAILAND
7.3.5.7. INDONESIA
7.3.5.8. VIETNAM
7.3.5.9. REST OF ASIA PACIFIC
7.4. REST OF WORLD
7.4.1. MARKET SIZE & ESTIMATES
7.4.2. KEY GROWTH ENABLERS
7.4.3. KEY CHALLENGE
7.4.4. KEY PLAYERS
7.4.5. REGIONAL ANALYSIS
7.4.5.1. LATIN AMERICA
7.4.5.2. MIDDLE EAST & AFRICA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGER & ACQUISITIONS
8.1.2. PRODUCT LAUNCH & DEVELOPMENTS
8.1.3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
8.1.4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
8.2. COMPANY PROFILE
8.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
8.2.2. ASTRAZENECA
8.2.3. BRISTOL -MYERS SQUIBB COMPANY
8.2.4. GENFIT SA
8.2.5. GILEAD SCIENCES, INC
8.2.6. MADRIGAL PHARMACEUTICALS
8.2.7. MERCK & CO
8.2.8. NOVARTIS AG
8.2.9. NOVO NORDISK
8.2.10. PFIZER INC
8.2.11. SIEMENS HEALTHINEERS
8.2.12. VIKING THERAPEUTICS
8.2.13. ZYDUS CADILA

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT - NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER
TABLE 2: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: GLOBAL SERUM BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: GLOBAL SERUM BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: GLOBAL HEPATIC FIBROSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: GLOBAL APOPTOSIS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: GLOBAL OXIDATIVE STRESS BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: GLOBAL OTHER TYPES MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: GLOBAL OTHER TYPES MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 15: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 16: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 17: GLOBAL PHARMA & CRO INDUSTRY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 18: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 19: GLOBAL DIAGNOSTIC LAB MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 20: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 21: GLOBAL ACADEMIC RESEARCH KEY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 22: GLOBAL HOSPITAL MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 23: GLOBAL HOSPITAL MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 24: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 25: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 26: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 27: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 28: LEADING PLAYERS OPERATING IN NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 29: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 30: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 31: LEADING PLAYERS OPERATING IN EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 32: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 33: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 34: LEADING PLAYERS OPERATING IN ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
TABLE 35: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 36: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 37: LEADING PLAYERS OPERATING IN REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET


LIST OF FIGURES
FIGURE 1: PORTER’S FIVE FORCE ANALYSIS
FIGURE 2: OPPORTUNITY MATRIX
FIGURE 3: VENDOR LANDSCAPE
FIGURE 4: KEY INVESTMENT INSIGHTS
FIGURE 5: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY TYPE, IN 2020
FIGURE 6: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY SERUM BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 7: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HEPATIC FIBROSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 8: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY APOPTOSIS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 9: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OXIDATIVE STRESS BIOMARKER, 2021-2028 (IN $ MILLION)
FIGURE 10: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY OTHER TYPES, 2021-2028 (IN $ MILLION)
FIGURE 11: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY END-USER, IN 2020
FIGURE 12: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY PHARMA & CRO INDUSTRY, 2021-2028 (IN $ MILLION)
FIGURE 13: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY DIAGNOSTIC LAB, 2021-2028 (IN $ MILLION)
FIGURE 14: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY ACADEMIC RESEARCH KEY, 2021-2028 (IN $ MILLION)
FIGURE 15: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, BY HOSPITAL, 2021-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 17: UNITED STATES NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 18: CANADA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 19: EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 20: GERMANY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 21: FRANCE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 22: UNITED KINGDOM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 23: ITALY NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 24: RUSSIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 25: BELGIUM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 26: POLAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 27: REST OF EUROPE NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 28: ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 29: CHINA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 30: JAPAN NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 31: AUSTRALIA & NEW ZEALAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 32: INDIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 33: SOUTH KOREA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 34: THAILAND NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 35: INDONESIA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 36: VIETNAM NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 37: REST OF ASIA PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 38: REST OF WORLD NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
FIGURE 39: LATIN AMERICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)
FIGURE 40: MIDDLE EAST & AFRICA NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET, 2021-2028 (IN $ MILLION)


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[非アルコール性脂肪性肝炎(NASH)バイオマーカーの世界市場2021-2028]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆